Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Economic Impact of Antimicrobial Resistance
John E. McGowan
Table 4
Elements of the economic impact of measures to deal with antimicrobial drug resistance, by perspective affected
| Element | Measurementa | Perspective affected directly |
|---|---|---|
| Develop new antimicrobial agents | Costs associated with drug development - Profit resulting from new drug's use | Drug industry, HCB, patient, society |
| Conduct surveillance | Cost of surveillance for infected and colonized patients (R) - Cost of surveillance for infected and colonized patients (S) | HCB |
| Implement isolation | Costs associated with barrier isolation (R) - Costs associated with barrier isolation (S) | HCW, visitor, patient, HCB |
| Adapt lab procedures | Costs associated with testing (R) - Costs associated with testing (S) | HCB, patient, society |
| Educate about resistance | Costs associated with educational programs (staff, patients) (R) -Costs associated with educational programs (staff, patients) (S) | HCW, patient, visitor, HCB |
| Improve drug administration | Costs for programs to improve drug administration (R) - Costs for programs to improve drug administration (S) | HCW, HCB |
| Improve drug choice | Costs for programs to improve drug choice (R) - Costs for programs to improve drug choice (S) | Prescribers, HCB |
aR = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business; HCW = health-care workers.
